Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Drop in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 240,900 shares, a drop of 21.7% from the August 15th total of 307,600 shares. Approximately 3.0% of the shares of the company are short sold. Based on an average trading volume of 328,700 shares, the short-interest ratio is currently 0.7 days. Based on an average trading volume of 328,700 shares, the short-interest ratio is currently 0.7 days. Approximately 3.0% of the shares of the company are short sold.

Senti Biosciences Stock Performance

Shares of SNTI opened at $1.39 on Friday. The stock has a 50 day simple moving average of $1.63 and a 200 day simple moving average of $2.62. Senti Biosciences has a 52-week low of $1.26 and a 52-week high of $16.94. The firm has a market capitalization of $36.36 million, a PE ratio of -0.16 and a beta of 2.06.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.30 million. Equities research analysts predict that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SNTI. Heights Capital Management Inc. bought a new position in Senti Biosciences during the 1st quarter worth $2,520,000. Nantahala Capital Management LLC bought a new position in Senti Biosciences during the 1st quarter worth $2,984,000. Geode Capital Management LLC increased its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the period. Finally, Armistice Capital LLC bought a new position in Senti Biosciences during the 2nd quarter worth $1,883,000. Institutional investors own 25.73% of the company’s stock.

Analysts Set New Price Targets

SNTI has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Senti Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, August 18th. Chardan Capital reiterated a “buy” rating and set a $12.00 price target on shares of Senti Biosciences in a research note on Friday, August 8th. Finally, Laidlaw initiated coverage on shares of Senti Biosciences in a research note on Friday, June 6th. They set a “buy” rating and a $5.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Senti Biosciences currently has an average rating of “Buy” and a consensus price target of $8.50.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.